Healthcare & Biotech

SHERIDAN, WYOMING - December 8, 2025 - Denali Therapeutics is facing another regulatory setback after the U.S. Food and Drug Administration (FDA) placed a clinical hold on DNL952, its enzyme replacement candidate for Pompe disease, citing preclinical hypersensitivity signals and demanding protocol changes before the company can start Phase I studies.

FDA Flags Hypersensitivity Risk Before First Human Dosing

The clinical hold, disclosed in an SEC filing, stems from "hypersensitivity reactions" observed in mouse models. While the agency has not required additional non-clinical studies, it is insisting on a more conservative first-in-human plan. Denali has been asked to lower the proposed starting dose for DNL952 and implement "revised inclusion criteria, adjusted stopping rules and unspecified safety monitoring commitments" before the program can proceed.

SHERIDAN, WYOMING - December 8, 2025 - Praxis Precision Medicines has doubled down on its neurology strategy with back-to-back updates: a Phase II win for its sodium current blocker relutrigine in rare developmental and epileptic encephalopathies (DEE) and a "successful" pre-NDA meeting for its essential tremor candidate ulixacaltamide, positioning the Boston biotech as a potential new commercial player in both ultra-rare epilepsy and movement disorders.

Relutrigine Study Stopped Early for Efficacy in DEE

Praxis has halted its mid-stage EMBOLD trial of relutrigine early, after an independent data monitoring board recommended the study "stop the study early for efficacy." The Phase II EMBOLD study is evaluating relutrigine in patients with DEE linked to SCN8A and SCN2A mutations, a small but highly underserved genetic epilepsy population with limited therapeutic options and high unmet medical need.

SHERIDAN, WYOMING - December 8, 2025 - Days after Johnson & Johnson reported a mid-stage failure for its anti-tau antibody posdinemab, Eisai is using the Clinical Trials on Alzheimer's Disease (CTAD) 2025 conference to argue that tau is still a viable target-if drug designers hit the right part of the protein-while investors and scientists pivot their attention to inflammation and vascular pathways.

Anti-tau Setbacks Raise the Bar for New Entrants

Tau-directed drugs have been among the most high-profile disappointments in Alzheimer's disease (AD) R&D. J&J's recent miss with posdinemab follows last year's Phase II failure of UCB's bepranemab and Eli Lilly's inability to replicate its amyloid success with the anti-tau candidate LY3372689. Collectively, these readouts have fed a narrative that tau may be an intractable or poorly understood target for disease modification.

SHERIDAN, WYOMING - December 8, 2025 - The CDC's Advisory Committee on Immunization Practices (ACIP) has triggered a major shift in U.S. newborn immunization policy, voting 8-3 to delay the hepatitis B vaccine for infants born to hepatitis B-negative mothers from the traditional birth dose to two months of age, despite decades of evidence and CDC messaging that the shot is safe, effective and critical for long-term protection.

A Narrow Vote to Delay the Birth Dose for Some Newborns

Under the new recommendation, only babies born to mothers who test positive for hepatitis B-or whose status is unknown-would still receive the birth dose. For infants of mothers who test negative, the vaccine can be delayed until two months, effectively dismantling the universal birth-dose strategy that has been in place for about 30 years.

SHERIDAN, WYOMING - December 8, 2025 - SprintRay's acquisition of the EnvisionTEC dental product portfolio marks a strategic step in the consolidation of the dental 3D printing market, expanding its materials ecosystem, reinforcing supply resilience and giving both SprintRay and EnvisionTEC users clearer long-term pathways in digital production.

What Changes for SprintRay Customers: More Materials, Same Workflow

For existing SprintRay practices and labs, the immediate impact is about breadth rather than disruption. The EnvisionTEC dental portfolio brings additional validated resin formulations that SprintRay is adapting for its own printers, which means customers gain more material options without having to invest in new hardware.

SHERIDAN, WYOMING - December 8, 2025 - As more practices adopt chairside 3D printing, many clinicians worry quietly about what it means for long-standing dental lab relationships-but rather than replacing labs, in-house production is reshaping them into higher-value, more strategic partnerships built around clearly defined roles and shared digital workflows.

From Full Lab Dependency to Hybrid Production

For years, the dominant model in restorative and appliance production has been full lab dependency: every crown, bridge, model, surgical guide, night guard or retainer went out the door to a third-party provider. In that setup, "Lab controls your timeline. Lab controls your cost per case. Lab capacity limits your capacity. Emergency cases wait on lab availability."

SHERIDAN, WYOMING - December 8, 2025 - Chairside 3D printing has moved from conference buzzword to everyday reality in U.S. dental practices, and SprintRay is positioning its ecosystem as a way for clinics to bring production in-house, compress treatment timelines, and turn same-day crowns into a strategic differentiator rather than a marketing slogan.

From Lab Dependency to In-Practice Production

At its core, "chairside" simply means producing the restoration in your own practice while the patient is still in your care, instead of sending cases to an external lab and waiting one to two weeks. Clinically, the workflow is familiar-examination, preparation, design and cementation remain the same-but the fabrication step moves from a third party you can't control to equipment in your operatory that you can.

SHERIDAN, WYOMING - December 4, 2025 - Life sciences dealmaking is regaining momentum after a period of macroeconomic caution, but new research from West Monroe shows that transaction volume alone will not determine who comes out ahead. Instead, success in the next wave of M&A will hinge on execution speed, AI and digital maturity, and the ability to integrate people and cultures without losing focus on the deal thesis.

Dealmaking Rebounds, but the Rules Have Changed

West Monroe's report, The Next Wave of Life Sciences M&A: Navigating Policy, Power, and Progress, combines practitioner insight with a survey of 250 private equity firms and strategic acquirers in life sciences. The findings point to a clear rebound in activity: 68% of respondents expect more acquisitions in the next two years, while only 7% plan no deals at all.

SHERIDAN, WYOMING - December 3, 2025 - AGC Biologics is expanding its Cell Line Development Center of Excellence through a new partnership with ATUM, integrating the Leap-In Transposase® expression platform to help biopharma developers move monoclonal antibodies and complex next-generation biologics into the clinic faster and more cost-effectively.

New options for faster, more flexible cell line development

As pressure grows to launch high-value biologics at lower cost, drug sponsors are looking for cell line development (CLD) solutions that combine speed, robustness and scalability. AGC Biologics' collaboration with ATUM adds a modern transposase-based expression platform to its CLD toolkit, creating a menu of fit-for-purpose options for standard monoclonals, multi-specific antibodies and other complex molecules.

SHERIDAN, WYOMING - December 3, 2025 - AGC Biologics has signed a new manufacturing agreement with AAVantgarde Bio to produce dual-vector AAV gene therapies for Stargardt disease and retinitis pigmentosa, positioning its BravoAAV™ platform at the center of next-generation treatments for inherited retinal disorders with no approved therapies.

Dual-vector AAV platform targets previously "untreatable" retinal genes

Under the deal, AGC Biologics will provide GMP manufacturing for AAVantgarde's two clinical-stage candidates: AAVB-039 for Stargardt disease, the most common inherited form of macular degeneration in children and young adults, and AAVB-081 for retinitis pigmentosa caused by Usher syndrome type 1B. Both programs are in Phase 1/2 trials, with AAVB-039 being tested in the U.S., UK and Europe, and AAVB-081 representing the first-ever dual AAV gene therapy in an ocular indication.